Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | TNNI3K | Q59H18 | 18/20 | 1.00 |
| ▸ | BRAF | P15056 | 13/20 | 0.88 |
| ▸ | RAF1 | P04049 | 1/20 | 0.66 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL9933362 | 0.97 | KDR (0.93) | KDRMAPK14TNNI3KBRAFRAF1 | |
| SCHEMBL9932861 | 0.94 | KDR (1.00) | KDRMAPK14TNNI3KBRAFRAF1 | |
| SCHEMBL31537739 | 0.94 | KDR (1.00) | KDRMAPK14TNNI3KBRAFRAF1 | |
| SCHEMBL9932510 | 0.94 | KDR (1.00) | KDRMAPK14TNNI3KBRAFRAF1 | |
| SCHEMBL9933250 | 0.91 | KDR (0.86) | KDRMAPK14TNNI3KBRAFRAF1 | |
| Trifluoroacetic Acid SCHEMBL9933224 | 0.91 | KDR (0.93) | KDRMAPK14TNNI3KBRAFRAF1 | |
| SCHEMBL9932595 | 0.91 | KDR (0.85) | KDRMAPK14TNNI3KBRAFRAF1 | |
| SCHEMBL9932042 | 0.90 | KDR (0.88) | KDRMAPK14TNNI3KBRAFRAF1 | |
| Trifluoroacetic Acid SCHEMBL9931925 | 0.90 | KDR (0.93) | KDRMAPK14TNNI3KBRAFRAF1 | |
| SCHEMBL9933269 | 0.90 | KDR (1.00) | KDRMAPK14TNNI3KBRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157482-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-06-21 | — | — | US | claimed |
| US-20120157482-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-06-21 | — | — | US | disclosed |
| US-20120157482-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-06-21 | — | — | US | disclosed |
| WO-2011025798-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157482-A1 | COMPOUNDS AND METHODS | NQO1, CYP1B1, CYP1A1 | KDR 1355/4885MAPK14 4682/4885TNNI3K 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.